-
公开(公告)号：US11053247B2
公开(公告)日：2021-07-06
申请号：US16451873
申请日：2019-06-25
发明人： Andrew K. Dilger , James R. Corte , Indawati De Lucca , Tianan Fang , Wu Yang , Yufeng Wang , Kumar Balashanmuga Pabbisetty , William R. Ewing , Yeheng Zhu , Ruth R. Wexler , Donald J. P. Pinto , Michael J. Orwat , Leon M. Smith, II
IPC分类号： C07D471/18 , C07F7/08 , C07D519/00 , C07D471/08 , C07D487/08
摘要： The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US20170158712A1
公开(公告)日：2017-06-08
申请号：US15437605
申请日：2017-02-21
发明人： Donald J. P. Pinto , James R. Corte , Paul J. Gilligan , Tianan Fang , Leon M. Smith, II , Yufeng Wang , Wu Yang , William R. Ewing
IPC分类号： C07D519/00 , C07D487/08 , C07D498/08 , C07D471/08
CPC分类号： C07D519/00 , C07D471/06 , C07D471/08 , C07D487/06 , C07D487/08 , C07D498/06 , C07D498/08
摘要： The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US09540323B2
公开(公告)日：2017-01-10
申请号：US14418023
申请日：2013-07-30
发明人： Alexandre L'Heureux , Sheldon Hiebert , Carol Hu , Patrick Y. S. Lam , John Lloyd , Zulan Pi , Jennifer X. Qiao , Carl Thibeault , George O. Tora , Wu Yang , Yufeng Wang , Tammy C. Wang , Michael S. Bowsher , Ruel Rejean
IPC分类号： C07D209/26 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/14 , C07D409/04 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D498/04 , C07D209/14 , C07D513/04 , C07D403/12 , C07D413/14 , C07D417/04
CPC分类号： C07D209/26 , C07D209/14 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D498/04 , C07D513/04
摘要： The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used medicaments.
摘要翻译： 本发明提供式（I）化合物：如说明书中所定义的式（I）和包含任何这些新化合物的组合物。 这些化合物是可以使用药物的P2Y1受体的拮抗剂。
-
公开(公告)号：US20160368923A1
公开(公告)日：2016-12-22
申请号：US15221142
申请日：2016-07-27
发明人： Andrew K. Dilger , James R. Corte , lndawati De Lucca , Tianan Fang , Wu Yang , Yufeng Wang , Kumar Balashanmuga Pabbisetty , William R. Ewing , Yeheng Zhu , Ruth R. Wexler , Donald J.P. Pinto , Michael J. Orwat , Leon M. Smith II
IPC分类号： C07D471/18 , C07D519/00 , C07F7/08 , C07D487/08 , C07D471/08
CPC分类号： C07D471/18 , C07D471/08 , C07D487/08 , C07D519/00 , C07F7/0814
摘要： The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译： 或立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号：US09453018B2
公开(公告)日：2016-09-27
申请号：US14872546
申请日：2015-10-01
发明人： Andrew K. Dilger , James R. Corte , Indawati De Lucca , Tianan Fang , Wu Yang , Yufeng Wang , Kumar Balashanmuga Pabbisetty , William R. Ewing , Yeheng Zhu , Ruth R. Wexler , Donald J. P. Pinto , Michael J. Orwat , Leon M. Smith, II
IPC分类号： C07D471/18 , C07D487/08 , C07B59/00 , C07D471/08 , C07D519/00
CPC分类号： C07D471/18 , C07D471/08 , C07D487/08 , C07D519/00 , C07F7/0814
摘要： The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译： 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号：US20150203492A1
公开(公告)日：2015-07-23
申请号：US14419002
申请日：2013-08-02
发明人： Wu Yang , James R. Corte , Paul J. Gilligan , Donald J.P. Pinto , William R. Ewing , Andrew K. Dilger , Yufeng Wang , Tianan Fang , Kumar B. Pabbisetty , Leon M. Smith, II
IPC分类号： C07D471/08 , C07D401/04 , C07D487/08 , C07D471/18 , C07H17/02
CPC分类号： C07D471/08 , C07C53/18 , C07D401/04 , C07D471/18 , C07D487/08 , C07D487/18 , C07H17/02
摘要： The present invention provides compounds of Formula (X): (Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译： 本发明提供式（X）的化合物：（式（X））或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa的双重抑制剂 血浆激肽释放酶。本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号：US09902742B2
公开(公告)日：2018-02-27
申请号：US15437605
申请日：2017-02-21
发明人： Donald J. P. Pinto , James R. Corte , Paul J. Gilligan , Tianan Fang , Leon M. Smith, II , Yufeng Wang , Wu Yang , William R. Ewing
IPC分类号： C07D487/08 , C07D519/00 , C07D471/08 , C07D498/08
CPC分类号： C07D519/00 , C07D471/06 , C07D471/08 , C07D487/06 , C07D487/08 , C07D498/06 , C07D498/08
摘要： The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US20180022753A1
公开(公告)日：2018-01-25
申请号：US15718431
申请日：2017-09-28
发明人： James R. Corte , Tianan Fang , Carl P. Decicco , Donald J.P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
IPC分类号： C07D487/04 , C07D487/14 , C07D471/14 , C07D487/18 , C07D471/18 , C07D498/06 , C07D487/16 , C07D487/06 , C07D498/08 , C07D498/04 , C07D487/08
CPC分类号： C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
摘要： The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US20170096429A1
公开(公告)日：2017-04-06
申请号：US15115314
申请日：2015-01-30
发明人： James R. Corte , Indawati De Lucca , Tianan Fang , Wu Yang , Yufeng Wang , Andrew K. Dilger , Kumar Balashanmuga Pabbisetty , William R. Ewing , Yeheng Zhu , Ruth R. Wexler , Donald J.P. Pinto , Michael J. Orwat , Leon M. Smith, II
IPC分类号： C07D471/08 , C07D403/14 , C07D471/18 , C07D487/08
CPC分类号： C07D471/08 , C07D403/06 , C07D403/14 , C07D471/18 , C07D487/08
摘要： The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US20170057961A1
公开(公告)日：2017-03-02
申请号：US15115319
申请日：2015-01-30
发明人： Andrew K. Dilger , James R. Corte , Indawati De Lucca , Tianan Fang , Wu Yang , Yufeng Wang , Kumar Balashanmuga Pabbisetty , William R. Ewing , Yeheng Zhu , Ruth R. Wexler , Donald J.P. Pinto , Michael J. Orwat , Leon M. Smith, II
IPC分类号： C07D471/18 , C07D487/08
CPC分类号： C07D471/18 , C07D487/08
摘要： The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译： 本发明提供式（Ia）化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.067 秒)
